<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990219</url>
  </required_header>
  <id_info>
    <org_study_id>19366A</org_study_id>
    <secondary_id>2021-001230-18</secondary_id>
    <nct_id>NCT04990219</nct_id>
  </id_info>
  <brief_title>A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis</brief_title>
  <official_title>Interventional, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 1 B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in&#xD;
      participants with multiple sclerosis (MS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants will be randomized to Lu AG06466 or placebo in a 2:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Spasticity Response</measure>
    <time_frame>Baseline to Week 5</time_frame>
    <description>Spasticity response defined as â‰¥30% increase from baseline in spasticity Numerical Rating Scale (NRS) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Week 5 in Spasticity NRS Score</measure>
    <time_frame>Baseline, Week 5</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Lu AG06466</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>Lu AG06466 - capsule</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a diagnosis of MS, as per the 2017 McDonald criteria.&#xD;
&#xD;
          -  The participant has clinically stable MS (such as no relapse and/or stable Expanded&#xD;
             Disability Status Scale [EDSS] or alternative clinical assessment score) for at least&#xD;
             6 months prior to screening.&#xD;
&#xD;
          -  The participant has ongoing spasticity for at least 90 days prior to screening.&#xD;
&#xD;
          -  The participant is on a stable regimen for at least 30 days prior to screening for all&#xD;
             medications and non pharmacological therapies, including therapies that are intended&#xD;
             to alleviate spasticity (for example, oral baclofen, tizanidine, dalfampridine), and&#xD;
             willing to remain on the same regimen throughout the duration of the study.&#xD;
&#xD;
          -  The participant reports walking impairment due to lower limb spasticity.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  The participant has any concomitant disease or disorder that has spasticity-like&#xD;
             symptoms or that may influence the participant's level of spasticity or the&#xD;
             participant's overall ability to participate in the study.&#xD;
&#xD;
          -  The participant has ambulation difficulties due to any concomitant disease or disorder&#xD;
             other than MS.&#xD;
&#xD;
          -  The participant has any known or suspected hypersensitivity to cannabinoids (CBs) or&#xD;
             any of the excipients of the investigational medicinal product (IMP).&#xD;
&#xD;
          -  The participant has a positive drug screening test, except for non-CB medications used&#xD;
             to treat a medical condition and reported as such by the participant; the participant&#xD;
             has a positive drug screen test for cannabis/delta-9-tetrahydrocannabinol.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Research - Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

